These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 37000317)
21. α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients. Liu J; Cai M; Chen J; Liao Y; Mai S; Li Y; Huang X; Liu Y; Zhang J; Kung H; Zeng Y; Zhou F; Xie D Eur J Cancer; 2014 Mar; 50(4):840-51. PubMed ID: 24388773 [TBL] [Abstract][Full Text] [Related]
22. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer. Chen S; Zhang N; Shao J; Wang T; Wang X J Cancer; 2019; 10(3):697-707. PubMed ID: 30719168 [No Abstract] [Full Text] [Related]
23. Identification of necroptosis-related subtypes, development of a novel signature, and characterization of immune infiltration in colorectal cancer. Sun M; Ji X; Xie M; Chen X; Zhang B; Luo X; Feng Y; Liu D; Wang Y; Li Y; Liu B; Xia L; Huang W Front Immunol; 2022; 13():999084. PubMed ID: 36544770 [TBL] [Abstract][Full Text] [Related]
24. Identification and Verification of Necroptosis-Related Gene Signature With Prognosis and Tumor Immune Microenvironment in Ovarian Cancer. Wang Z; Chen G; Dai F; Liu S; Hu W; Cheng Y Front Immunol; 2022; 13():894718. PubMed ID: 35812403 [TBL] [Abstract][Full Text] [Related]
25. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer. Lyu X; Wang P; Qiao Q; Jiang Y BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019 [TBL] [Abstract][Full Text] [Related]
26. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance. Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771 [TBL] [Abstract][Full Text] [Related]
27. Infiltration related miRNAs in bladder urothelial carcinoma. Xie P; Xu F; Cheng W; Gao J; Zhang Z; Ge J; Wei Z; Xu X; Liu Y J Huazhong Univ Sci Technolog Med Sci; 2012 Aug; 32(4):576-580. PubMed ID: 22886973 [TBL] [Abstract][Full Text] [Related]
28. A novel 6-gene signature derived from tumor-infiltrating T cells and neutrophils predicts survival of bladder urothelial carcinoma. Zou X; Wei Y; Qi T; Wang X; Zuo W; Wang T; Zhu W; Zhou X Aging (Albany NY); 2021 Dec; 13(23):25496-25517. PubMed ID: 34905506 [TBL] [Abstract][Full Text] [Related]
29. Mass cytometry reveals immune atlas of urothelial carcinoma. Zhang Q; Zhang W; Lin T; Lu W; He X; Ding Y; Chen W; Diao W; Ding M; Shen P; Guo H BMC Cancer; 2022 Jun; 22(1):677. PubMed ID: 35725444 [TBL] [Abstract][Full Text] [Related]
30. Identification of necroptosis-related signature and tumor microenvironment infiltration characteristics in lung adenocarcinoma. Liu T; Guo L; Liu G; Dai Z; Wang L; Lin B; Hu X; Wang J; Zhang J Lung Cancer; 2022 Oct; 172():75-85. PubMed ID: 36027854 [TBL] [Abstract][Full Text] [Related]
31. Identification and validation of necroptosis-related gene signatures to predict clinical outcomes and therapeutic responses in acute myeloid leukemia. Wen XM; Xu ZJ; Ma JC; Xia PH; Jin Y; Chen XY; Qian W; Lin J; Qian J Aging (Albany NY); 2023 Nov; 15(24):14677-14702. PubMed ID: 37993258 [TBL] [Abstract][Full Text] [Related]
32. Comprehensive Genomic Analysis of Puerarin in Inhibiting Bladder Urothelial Carcinoma Cell Proliferation and Migration. Ma YY; Zhang GJ; Liu PF; Liu Y; Ding JC; Xu H; Hao L; Pan D; Wang HL; Wang JK; Xu P; Shi ZD; Pang K Recent Pat Anticancer Drug Discov; 2024; 19(4):516-529. PubMed ID: 37694778 [TBL] [Abstract][Full Text] [Related]
33. Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway. Huang Z; Zhong Z; Zhang L; Wang X; Xu R; Zhu L; Wang Z; Hu S; Zhao X Sci Rep; 2015 Aug; 5():12807. PubMed ID: 26239046 [TBL] [Abstract][Full Text] [Related]
34. Pan-Cancer analyses of Necroptosis-Related genes as a potential target to predict immunotherapeutic outcome. Zhou Z; Wu J; Ma W; Dong F; Wang J J Cell Mol Med; 2023 Jan; 27(2):204-221. PubMed ID: 36583248 [TBL] [Abstract][Full Text] [Related]
35. Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma. Zhu J; Han T; Zhao S; Zhu Y; Ma S; Xu F; Bai T; Tang Y; Xu Y; Liu L Front Oncol; 2022; 12():933210. PubMed ID: 35875102 [TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer. Song S; Zhang M; Xie P; Wang S; Wang Y Front Immunol; 2022; 13():978909. PubMed ID: 36341328 [TBL] [Abstract][Full Text] [Related]
37. MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis. Xiang L; Zeng Q; Liu J; Xiao M; He D; Zhang Q; Xie D; Deng M; Zhu Y; Liu Y; Bo H; Liu X; Zhou M; Xiong W; Zhou Y; Zhou J; Li X; Cao K Sci Bull (Beijing); 2021 Sep; 66(17):1773-1788. PubMed ID: 36654385 [TBL] [Abstract][Full Text] [Related]
38. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer. Zhao Z; Liu S; Sun R; Zhu W; Zhang Y; Liu T; Li T; Jiang N; Guo H; Yang R Front Immunol; 2023; 14():1085476. PubMed ID: 36960067 [TBL] [Abstract][Full Text] [Related]
39. Bulk and single-cell transcriptome profiling reveal necroptosis-based molecular classification, tumor microenvironment infiltration characterization, and prognosis prediction in colorectal cancer. Luo W; Xiang W; Gan L; Che J; Li J; Wang Y; Han L; Gu R; Ye L; Wang R; Zhang X; Xu Y; Dai W; Mo S; Li Q; Cai G J Transl Med; 2022 May; 20(1):235. PubMed ID: 35590418 [TBL] [Abstract][Full Text] [Related]
40. Identification of necroptosis-related gene signature and characterization of tumour microenvironment infiltration in non-small-cell lung cancer. Dai J; Fu Y J Cell Mol Med; 2022 Sep; 26(17):4698-4709. PubMed ID: 35871768 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]